Cerus Corporation Invites You to Join a Webcast of its First Quarter Conference Call.

Business Editors & Health/Medical Writers

CONCORD, Calif.--(BW HealthWire)--April 12, 2002

In conjunction with Cerus Corporation's First Quarter Financial Results release, you are invited to listen to its conference call that will be broadcast live over the Internet on April 25, 2002 at 4:30 p.m. ET with Stephen Isaacs, president and CEO, Greg Schafer, CFO, Laurence Corash, M.D., VP, Medical Affairs and Jim Vaughn, R.Ph., VP Marketing of Cerus Corporation.

         What:      Cerus Corporation First Quarter Financial
                    Results as well as an Update on Progress and
                    Future Outlook

         When:      Thursday, April 25, 2002 at 4:30 p.m. ET

         Where:     http://www.videonewswire.com/event.asp?id=4286

         How:       Live over the Internet -- Simply log on to the
                    web at the address above

         Contact:   Lisa Luttinger/Cerus Corporation,
                    925/288-6036

Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(R) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. In collaboration with its partner, Baxter Healthcare Corporation, the company has submitted a CE Mark application seeking European approval for the INTERCEPT Platelet System, and has begun the regulatory submission process in the United States. The companies are preparing to begin the U.S. regulatory submission process for the INTERCEPT Plasma system, which will be followed by a CE Mark application for this product. The INTERCEPT Red Blood Cell System is in Phase III clinical trial stage. The Concord, Calif.-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

Helinx is a trademark of Cerus Corporation.

Intercept is a trademark of Baxter International, Inc.

If you are unable to participate during the live webcast, the

call will be archived for 72 hours on the Website

www.cerus.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from www.real.com/products/player/index.html, and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [e-mail].)